class='kwd-title'>Keywords: Bioprosthetic valve,'/> Bioprosthetic Valve Thrombosis while on a Novel Oral Anticoagulant for Atrial Fibrillation
首页> 美国卫生研究院文献>CASE : Cardiovascular Imaging Case Reports >Bioprosthetic Valve Thrombosis while on a Novel Oral Anticoagulant for Atrial Fibrillation
【2h】

Bioprosthetic Valve Thrombosis while on a Novel Oral Anticoagulant for Atrial Fibrillation

机译:新型口服抗凝剂对房颤进行生物人工瓣膜血栓形成

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

class="kwd-title">Keywords: Bioprosthetic valve, Thrombosis, Anticoagulation, Atrial fibrillation class="head no_bottom_margin" id="sec1title">IntroductionValvular heart disease (VHD) affects >100 million people worldwide. Surgical valve replacement is currently offered for many patients with VHD, and 80% of devices are bioprosthetic valves (BPVs).Thromboembolism is a major life-threatening complication in patients with prosthetic heart valves. Anticoagulation with vitamin K antagonists (VKAs) is considered reasonable 3 to 6 months postoperatively to prevent BPV thrombosis (BPVT). However, the appropriate antithrombotic therapy for preventing BPVT in the setting of comorbid atrial fibrillation (AF) is not well defined. The increasing availability and widespread use of direct oral anticoagulants (DOACs) raises questions of safety in patients with BPVs and AF.There are currently no randomized controlled trials using DOACs in patients with BPVs and AF. We present the case of a patient with mitral and aortic BPVs with comorbid AF who was treated with a DOAC and ultimately developed thrombosis of both valves.
机译:<!-fig ft0-> <!-fig @ position =“ anchor” mode =文章f4-> <!-fig mode =“ anchred” f5-> <!-fig / graphic | fig / alternatives / graphic mode =“ anchored” m1-> class =“ kwd-title”>关键字:生物人工瓣膜,血栓形成,抗凝,心房颤动 class =“ head no_bottom_margin” id =“ sec1title “>简介瓣膜性心脏病(VHD)影响全球超过1亿人。目前,许多VHD患者可使用外科瓣膜置换术,其中80%的设备是生物人工瓣膜(BPV)。血栓栓塞是严重威胁生命的人工瓣膜并发症。维生素K拮抗剂(VKA)的抗凝被认为在术后3至6个月是合理的,以预防BPV血栓形成(BPVT)。然而,在合并房颤的情况下预防BPVT的适当抗血栓治疗方法尚未明确。直接口服抗凝剂(DOAC)的可用性不断提高和广泛使用提出了BPV和AF患者的安全性问题。目前尚无针对BPV和AF患者使用DOAC的随机对照试验。我们介绍了二尖瓣和主动脉BPV合并房颤的患者,该患者接受DOAC治疗并最终发展为两个瓣膜血栓形成。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号